MNPR - Monopar Therapeutics: Strong Data, But There Are Risks
2025-03-04 04:54:57 ET
Summary
- Monopar Therapeutics' lead asset, ALXN1840, shows superior copper mobilization in Wilson Disease compared to standard care, with positive phase 3 trial results.
- The market for Wilson Disease treatments is small, with limited pricing power due to existing generic therapies.
- Financially, Monopar has a cash runway until 2026 but will need additional funds for commercialization efforts.
- Key risks include the need for future funding and competition from Pfizer's gene therapy, VTX-801, which is still years from market.
Monopar Therapeutics ( MNPR ) is a small company with a late-stage asset acquired late last year from Alexion/AstraZeneca (AZN), that had positive data from a phase 3 trial in a rare disease program in Wilson Disease. It has a couple of other programs in active phase 1 clinical trials, and a few more preclinical programs. Monopar acquired this asset on October 24, 2024. If you see the chart for MNPR, on that day, the stock went from below $5 to above $30 on the news. It did a small $19mn offering on October 28, and the stock dropped 50%, trading at %16ish. However, it still remained strong and continued to climb until mid-February, when there was another drop for no discernible reason....
Monopar Therapeutics: Strong Data, But There Are Risks